Anticipate Dispensing Post-Exposure Prophylaxis for COVID-19
You'll hear buzz about casirivimab/imdevimab (Regen-COV), the first med authorized to PREVENT COVID-19 after exposure.
This monoclonal antibody is already authorized to TREAT certain outpatients 12 or older with COVID-19 who are at high risk for severe illness...such as those with diabetes, obesity, etc.
Now it may be used for COVID-19 prevention if these same high-risk patients are exposed to the virus...as "post-exposure prophylaxis."
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote